NCT01174121: An ongoing trial by National Cancer Institute (NCI)
This trial is ongoing. It must report results 4 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT01174121 |
|---|---|
| Title | A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 26, 2010 |
| Completion date | Dec. 27, 2028 |
| Required reporting date | Dec. 27, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | None |